Trump Calls Reducing Drug Prices One of His 'Top Priorities for the Year'

Trump speaking during his State of the Union address.

On Tuesday night, President Trump gave his first State of the Union speech since taking office last year. Trump addressed many issues facing the nation, including jobs, infrastructure, immigration and health care.

Trump addressed people living with terminal illnesses, stating that those living with life-threatening conditions should have immediate access to experimental therapies.

Trump also spoke about the Food and Drug Administration, and the agency’s recent push to approve more new and generic drugs and medical devices.

The president added that one of his “top priorities” for 2018 is to lower drug prices.

Related:​ The First Time Someone Believed My Illness Was Real

Despite calls to make health care more accessible, the Trump administration has taken multiple steps to dismantle the Affordable Care Act and has put Medicaid funding in jeopardy. Trump’s tax bill removed the individual mandate — requiring people to sign-up for insurance or pay a fee — as of 2019, which experts believe will destabilize the marketplace and drive up premiums. According to the Congressional Budget Office, under the new tax bill, Medicaid could face an annual cut of $25 billion.

Trump also addressed the opioid epidemic. “

Trump did not mention those who use opioids for chronic pain or how the epidemic would be addressed. In August, Trump called the opioid epidemic a national emergency, a declaration which freed up only $57,000 from the U.S.’s Public Health Emergency Fund.

Related:​ When a Reality TV Star With Tourette’s Recalled My Fears About Having a Hereditary Disease

Got a tip for our news team? Send it to news@themighty.com.

Read more stories like this on The Mighty:

How to Transform Health Trials Into Teaching Moments

My Declassified Prednisone Survival Guide

15 Steps for Taking Back Control of Your Life and Your Health

If Someone With Chronic Illness Says They’re Tired, Please Think Before Responding, ‘Me Too’

Leave a Reply